Literature DB >> 8011819

Efficacy of a short course (10 days) of high-dose meglumine antimonate with or without interferon-gamma in treating cutaneous leishmaniasis in Guatemala.

B A Arana1, T R Navin, F E Arana, J D Berman, F Rosenkaimer.   

Abstract

Sixty-six Guatemalan men with parasitologically confirmed cutaneous leishmaniasis, due most commonly to Leishmania braziliensis, were randomly assigned to receive one of three treatment regimens: meglumine antimonate (meglumine) for 20 days; meglumine for 10 days; and meglumine for 10 days plus alternate-day injections of interferon-gamma. In each group, meglumine was given intravenously as 20 mg of antimony/(kg of body weight.d). All treatment regimens were associated with similar response rates: the lesions of 19 (90%) of 21 patients who received meglumine for 20 days, 18 (90%) of 20 patients who received meglumine for 10 days, and all 22 patients who received meglumine plus interferon-gamma were completely reepithelialized by 13 weeks. In addition, for patients receiving all treatment regimens, test-of-cure cultures for Leishmania were negative and reactivation of lesions did not occur during 12 months of follow-up. The high efficacy of our 10-day course of meglumine indicates that the currently recommended duration of 20 days may be unnecessary for infections caused by L. braziliensis and suggests that a 10-day course of high-dose antimony should be tested as therapy for cutaneous leishmaniasis in other geographic areas.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8011819     DOI: 10.1093/clinids/18.3.381

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  9 in total

Review 1.  Therapeutic options for old world cutaneous leishmaniasis and new world cutaneous and mucocutaneous leishmaniasis.

Authors:  Begoña Monge-Maillo; Rogelio López-Vélez
Journal:  Drugs       Date:  2013-11       Impact factor: 9.546

Review 2.  Current and future clinical applications of interferon-gamma in host antimicrobial defense.

Authors:  H W Murray
Journal:  Intensive Care Med       Date:  1996-10       Impact factor: 17.440

3.  Establish an allele-specific real-time PCR for Leishmania species identification.

Authors:  Yun Wu; Mengyuan Jiang; Shaogang Li; Nicholas R Waterfield; Guowei Yang
Journal:  Infect Dis Poverty       Date:  2022-06-02       Impact factor: 10.485

4.  Clinical and laboratory profiles of patients with early spontaneous healing in cutaneous localized leishmaniasis: a historical cohort study.

Authors:  Carla Oliveira-Ribeiro; Maria Inês Fernandes Pimentel; Raquel de Vasconcellos Carvalhaes Oliveira; Aline Fagundes; Maria de Fatima Madeira; Cintia Xavier Mello; Eliame Mouta-Confort; Claudia Maria Valete-Rosalino; Erica de Camargo Ferreira Vasconcellos; Marcelo Rosandiski Lyra; Leonardo Pereira Quintella; Liliane de Fatima Antonio; Armando Schubach; Fatima Conceição-Silva
Journal:  BMC Infect Dis       Date:  2017-08-10       Impact factor: 3.090

5.  The combination therapy of meglumine antimoniate and oxiranes (epoxy-α-lapachone and epoxymethyl-lawsone) enhance the leishmanicidal effect in mice infected by Leishmania (Leishmania) amazonensis.

Authors:  Luiz Filipe Gonçalves-Oliveira; Franklin Souza-Silva; Luzia Monteiro de Castro Côrtes; Laura Barral Veloso; Bernardo Acácio Santini Pereira; Lea Cysne-Finkelstein; Guilherme Curty Lechuga; Saulo Cabral Bourguignon; Fernando Almeida-Souza; Kátia da Silva Calabrese; Vitor Francisco Ferreira; Carlos Roberto Alves
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2019-08-12       Impact factor: 4.077

Review 6.  Route map for the discovery and pre-clinical development of new drugs and treatments for cutaneous leishmaniasis.

Authors:  Diana Caridha; Brian Vesely; Katrien van Bocxlaer; Byron Arana; Charles E Mowbray; Sima Rafati; Silvia Uliana; Rosa Reguera; Mara Kreishman-Deitrick; Richard Sciotti; Pierre Buffet; Simon L Croft
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2019-06-20       Impact factor: 4.077

Review 7.  Treatment of Cutaneous Leishmaniasis and Insights into Species-Specific Responses: A Narrative Review.

Authors:  Rajamanthrilage Kasun Madusanka; Hermali Silva; Nadira D Karunaweera
Journal:  Infect Dis Ther       Date:  2022-02-22

Review 8.  Interventions for American cutaneous and mucocutaneous leishmaniasis: a systematic review update.

Authors:  Ludovic Reveiz; Ana Nilce Silveira Maia-Elkhoury; Rubén Santiago Nicholls; Gustavo Adolfo Sierra Romero; Zaida E Yadon
Journal:  PLoS One       Date:  2013-04-29       Impact factor: 3.240

9.  Interventions for American cutaneous and mucocutaneous leishmaniasis.

Authors:  Mariona Pinart; José-Ramón Rueda; Gustavo As Romero; Carlos Eduardo Pinzón-Flórez; Karime Osorio-Arango; Ana Nilce Silveira Maia-Elkhoury; Ludovic Reveiz; Vanessa M Elias; John A Tweed
Journal:  Cochrane Database Syst Rev       Date:  2020-08-27
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.